NCT06908382View on ClinicalTrials.gov

Neoadjuvant QL1706 Therapy for ESCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 28, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions
Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Iparomlimab and Tuvonralimab Injection

QL1706 (5 mg/kg, q3w) +Paclitaxel for injection (albumin bound) (260mg/m2 D1, q3w)+cisplatin (75mg/m2 D1, q3w)/carboplatin (AUC 5 D1) ， 3 cycles

Trial Locations (1)

250000

RECRUITING

Shandong Provincial Hospital, Jinan

All Listed Sponsors
lead

Shandong Provincial Hospital

OTHER_GOV